Epidermal DNA vaccine for influenza is immunogenic in humans

Vaccine

Volumn 24, Issue 21, 2006, Pages 4475-4481

  Drape, Robert J ^a   Macklin, Michael D ^a   Barr, Lori J ^a   Jones, Suzanne ^a   Haynes, Joel R ^a   Dean, Hansi J ^a  

^a PowderJect Vaccines Inc   (United States)

Author keywords

Clinical trial; DNA vaccine; Epidermis; Influenza

Indexed keywords

DNA VACCINE; HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EPIDERMIS; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INJECTION SITE REACTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION; SINGLE DRUG DOSE; SKIN MANIFESTATION;

ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPIDERMIS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, DNA;

EID: 33646830816     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.012     Document Type: Article

References (44)

1. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24 1 (1986) 157-160
2. Clements M.L., Betts R.F., and Murphy B.R. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1 8379 (1984) 705-708
3. Remarque E.J. Influenza vaccination in elderly people. Exp Gerontol 34 3 (1999) 445-452
4. Nguyen-Van-Tam J.S., and Hampson A.W. The epidemiology and clinical impact of pandemic influenza. Vaccine 21 16 (2003) 1762-1768
5. Subbarao K., and Katz J. Avian influenza viruses infecting humans. Cell Mol Life Sci 57 12 (2000) 1770-1784
6. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363 9409 (2004) 587-593
7. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21 16 (2003) 1776-1779
8. Webster R.G. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis 28 2 (1999) 225-229
9. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 80 Pt 10 (1999) 2559-2564
10. Chen Z., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 17 7-8 (1999) 653-659
11. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 72 2 (1998) 1491-1496
12. Ulmer J.B. Influenza DNA vaccines. Vaccine 20 Suppl. 2 (2002) S74-S76
13. Donnelly J.J., Friedman A., Ulmer J.B., and Liu M.A. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15 8 (1997) 865-868
14. Okuda K., Ihata A., Watabe S., Okada E., Yamakawa T., Hamajima K., et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19 27 (2001) 3681-3691
15. Kodihalli S., Haynes J.R., Robinson H.L., and Webster R.G. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol 71 5 (1997) 3391-3396
16. Kodihalli S., Goto H., Kobasa D.L., Krauss S., Kawaoka Y., and Webster R.G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73 3 (1999) 2094-2098
17. Kodihalli S., Kobasa D.L., and Webster R.G. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18 23 (2000) 2592-2599
18. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., and Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 15 1 (1997) 71-78
19. Fynan E.F., Robinson H.L., and Webster R.G. Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine. DNA Cell Biol 12 9 (1993) 785-789
20. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90 24 (1993) 11478-11482
21. Johnson P.A., Conway M.A., Daly J., Nicolson C., Robertson J., and Mills K.H. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol 81 Pt 7 (2000) 1737-1745
22. Justewicz D.M., Morin M.J., Robinson H.L., and Webster R.G. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol 69 12 (1995) 7712-7717
23. Lunn D.P., Soboll G., Schram B.R., Quass J., McGregor M.W., Drape R.J., et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 17 18 (1999) 2245-2258
24. Montgomery D.L., Shiver J.W., Leander K.R., Perry H.C., Friedman A., Martinez D., et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 12 9 (1993) 777-783
25. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., and Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 176 Suppl. 1 (1997) S50-S55
26. Webster R.G., Fynan E.F., Santoro J.C., and Robinson H. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 12 16 (1994) 1495-1498
27. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1 6 (1995) 583-587
28. Chen Z., Sahashi Y., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16 16 (1998) 1544-1549
29. Chen Z., Kadowaki S., Hagiwara Y., Yoshikawa T., Sata T., Kurata T., et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 19 11-12 (2001) 1446-1455
30. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 7-8 (2000) 764-778
31. Rottinghaus S.T., Poland G.A., Jacobson R.M., Barr L.J., and Roy M.J. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21 31 (2003) 4604-4608
32. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., and Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 22 (1999) 2826-2829
33. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance. US Department of Health and Human Services, Public Health Service, Centers for Disease Control 1982:B17-35.
34. Kemble G., and Greenberg H. Novel generations of influenza vaccines. Vaccine 21 16 (2003) 1789-1795
35. Betts R.F., and Treanor J.J. Approaches to improved influenza vaccination. Vaccine 18 16 (2000) 1690-1695
36. Dean H.J., Fuller D., and Osorio J.E. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 26 5-6 (2003) 373-388
37. CPMP. Note for guidance on harmonization of requirements for influenza vaccine, in CPMP/BWP/214/96; 1997.
38. Beyer W.E., Palache A.M., de Jong J.C., and Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20 9-10 (2002) 1340-1353
39. Treanor J., and Wright P.F. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 115 (2003) 97-104
40. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 6 (2003) 729-735
41. Moorthy V.S., McConkey S., Roberts M., Gothard P., Arulanantham N., Degano P., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21 17-18 (2003) 1995-2002
42. Pilling A.M., Harman R.M., Jones S.A., McCormack N.A., Lavender D., and Haworth R. The assessment of local tolerance, acute toxicity, and DNA biodistribution following particle-mediated delivery of a DNA vaccine to minipigs. Toxicol Pathol 30 3 (2002) 298-305
43. Arrington J., Braun R.P., Dong L., Fuller D.H., Macklin M.D., Umlauf S.W., et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 76 9 (2002) 4536-4546
44. Nagata T., Uchijima M., Yoshida A., Kawashima M., and Koide Y. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 261 2 (1999) 445-451